StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Equities research analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Lake Street Capital assumed coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective for the company.

InspireMD Trading Up 0.7 %

NYSE:NSPR opened at $2.70 on Wednesday. The company has a market capitalization of $80.16 million, a P/E ratio of -3.60 and a beta of 0.88. The firm has a 50-day moving average price of $2.86 and a two-hundred day moving average price of $2.76. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.80.

Institutional Trading of InspireMD

Large investors have recently made changes to their positions in the stock. Parkman Healthcare Partners LLC lifted its holdings in InspireMD by 721.2% in the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock valued at $2,248,000 after purchasing an additional 750,635 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of InspireMD in the fourth quarter valued at approximately $191,000. Northern Trust Corp raised its position in shares of InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after buying an additional 24,452 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in shares of InspireMD by 153.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after buying an additional 18,233 shares during the period. Finally, Legato Capital Management LLC acquired a new stake in InspireMD during the fourth quarter worth approximately $47,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.